Emergency percutaneous cardiopulmonary bypass support in cardiogenic shock from acute myocardial infarction

Emergency percutaneous cardiopulmonary bypass support was instituted in 8 consecutive patients, ages 42 to 80 years, in cardiogenic shock for 30 to 180 minutes (mean 106) due to acute myocardial infarction. The location of the infarction was inferior in 4, anterior in 3 and lateral in 1. Four patients had a history of prior myocardial infarction. Two patients were in cardiac arrest; the remaining 6 had a mean blood pressure of 43 to 55 mm Hg before the bypass. Five had pulmonary capillary Wedge pressure greater than or equal to 20 mm Hg. One patient, with a right ventricular infarction, had a pulmonary wedge pressure of 10 mm Hg. Percutaneous insertion of 20Fr cannulas was carried out. Flow rates of 3.2 to 5.2 liters/min were achieved. Two patients in cardiac arrest regained consciousness while still in ventricular fibrillation or asystole. Left ventricular ejection fraction ranged from 17 to 40% (mean 32). One patient had left main, 4 had multivessel, and 4 had 1-vessel coronary disease. Seven patients had successful angioplasty of 15 of 16 lesions attempted, with all infarct-related vessels successfully dilated. One patient had lesions unsuitable for either bypass or angioplasty and died. Need for blood transfusion was the most frequent complication. One patient required surgical repair of the femoral artery. All 7 patients are alive at a mean follow-up of 8.2 months. It is concluded that cardiopulmonary bypass can be safely instituted percutaneously, hemodynamically stabilize patients in cardiogenic shock and facilitate emergency complex coronary angioplasty, which may be life-saving.     

Emergency cardiopulmonary bypass support in patients with severe cardiogenic shock after acute myocardial infarction

Summary A total of 16 patients who developed severe cardiogenic shock were resuscitated with a percutaneous cardiopulmonary support system (PCPS). The etiology of shock was acute myocardial infarction (n = 7), or post-infarction left-ventricular (LV) free wall rupture (n = 9). After successful resuscitation with the PCPS, 15 patients underwent therapeutic interventions: closure of an LV rupture (n = 9), coronary artery bypass grafting (n = 4), percutaneous transluminal angioplasty (n = 1), and percutaneous transluminal coronary recanalization (n = 1). Of the 16 patients, 14 were weaned from PCPS or standard cardiopulmonary bypass. Six patients survived longer than 30 days, 3 (19%) of whom were discharged from the hospital. The long-term survival rate in the 6 patients who underwent coronary revascularization was 33% (2/6). Of the 9 patients with LV free wall rupture, 1 was discharged from the hospital. Even though it cannot be concluded, from this small number of patients, that cardiopulmonary resuscitation using PCPS improves survival, it appears that PCPS is a powerful resuscitative modality for seriously ill patients with acute myocardial infarction or LV rupture.     

Salbutamol in cardiogenic shock complicating acute myocardial infarction.

Intravenous salbutamol (13 microgram/min) has been given to 31 patients with cardiogenic shock complicating acute myocardial infarction. Haemodynamic measurements were made in nine of these patients. Salbutamol increased cardiac index by 41 per cent from 1.25 +/- 0.06 l/min per m2 to 1.76 +/- 0.19 l/min per m2 and decreased systemic vascular resistance by 16 per cent from 26.2 +/- 1.9 units to 21.9 +/- 2.1 units. Heart rate rose by 13 per cent from 95 +/- 4.5 beats/min to 106 +/- 6.0 beats/min. Pulmonary artery end-diastolic pressure fell from 20.6 +/- 1.7 mmHg to 16.9+/- 1.9 mmHg. Of the 31 patients, eight survived to leave hospital (27%). Five of the survivors had initial low heart rates and in these patients the clinical improvement was probably attributable to the positive chronotropic action of salbutamol. In the remaining three survivors clinical improvement was probably a result of salbutamol mediated afterload reduction. Salbutamol may be useful in the treatment of cardiogenic shock and pump failure complicating acute myocardial infarction.     

Primary angioplasty for cardiogenic shock complicating acute myocardial infarction.

To evaluate the role of primary percutaneous transluminal coronary angioplasty in cardiogenic shock, 53 patients admitted with the diagnosis of acute myocardial infarction and cardiogenic shock were studied. Thirty-five (66.0%) patients received intravenous thrombolytic therapy (streptokinase 15 lac units) and 18 (34.0%) underwent primary percutaneous transluminal coronary angioplasty. There was no significant difference in the mean age, risk factor profile, presence of prior myocardial infarction, site of myocardial infarction and cardiac enzyme levels at presentation between the two groups. More male patients were present in the group undergoing primary percutaneous transluminal coronary angioplasty (94.44% vs 68.57%; p = 0.04). The time delay between the onset of symptoms and presentation to the hospital did not differ significantly between the two groups (318.9 vs 320.0 minutes; p = NS). In the primary percutaneous transluminal coronary angioplasty group, 17 patients had a single infarct-related artery and one had both left anterior descending and right coronary artery occlusion. Thus in 18 patients, 19 vessels were attempted. Angiographic success (< 50% residual stenosis) was achieved in 15 (78.94%) vessels of which TIMI III flow was achieved in 10 (52.63%) vessels and TIMI II flow in five (26.31%). Intra-aortic balloon pump was needed in five (27.77%) patients undergoing coronary angioplasty. In-hospital mortality was 27.77 percent in patients undergoing primary percutaneous transluminal coronary angioplasty and 57.14 percent in patients receiving intravenous thrombolytic therapy (p = 0.04). In the thrombolytic therapy group, mortality was higher (85.91%) in patients presenting six hours or later after the onset of symptoms as compared to those presenting in less than six hours of the onset of symptoms (50%). In primary percutaneous transluminal coronary angioplasty group, mortality was 21.42 percent in patients with successful and 50 percent in patients with failed angioplasty. Thus, in patients with acute myocardial infarction and cardiogenic shock, an aggressive invasive strategy with primary percutaneous transluminal coronary angioplasty, as compared to intravenous thrombolytic therapy, is helpful in reducing in-hospital mortality.     

Management of cardiogenic shock complicating acute myocardial infarction: A review

Despite advances in percutaneous coronary interventions and their widespread use, mortality in patients presenting with acute myocardial infarction (MI) complicated by cardiogenic shock (CS) has remained very high, and treatment options are limited. Limited evidences exist, supporting many of the routinely used therapies in treating these patients. In the present article, we discuss CS complicating MI in general and an update on the currently available treatment options, including inotropes and vasopressor, coronary revascularization, mechanical circulatory support devices, mechanical complications, and long‐term outcomes.     

Right ventricular infarction with cardiogenic shock treated with percutaneous cardiopulmonary support: a case report.

A patient with a right ventricular infarction was resuscitated with percutaneous cardiopulmonary support (PCPS), after attempts at reperfusion, high-dose inotropic support and intra-aortic balloon counterpulsation failed to improve the hemodynamic compromise. Emergency PCPS improved the cardiogenic shock and the reduced right ventricular load, allowing the ischemic right ventricle to recover in the setting of unsuccessful reperfusion. This case demonstrates the use of PCPS as a hemodynamic support device for spontaneous recovery of the ischemic right ventricle. PCPS may be a potential therapy for patients with right ventricular infarction.     

急性心肌梗死合并心原性休克47例治疗和死亡原因分析

目的 评价急性心肌梗死合并心原性休克47例患者的临床疗效,寻求降低病死率、改善预后的措施.方法 回顾性分析2002年1月至2007年5月共47例心肌梗死合并心原性休克患者,运用心血管活性药物、主动脉内球囊反搏(IABP)、介入手术或冠状动脉旁路移植术的治疗效果.结果 IABP治疗47例(100%),再血管化治疗41例(87.3%),死亡17例(36.2%).经药物和IABP治疗,在接受再血管化前死亡的患者占死亡数的35.3%(6/17),再血管化后死亡的患者占死亡数的64.7%(11/17).死于心功能衰竭者9例,死于肾功能衰竭和呼吸功能衰竭者8例.11例出现急性肾功能衰竭的患者全部死亡.急性肾功能衰竭(r=0.734,P=0.000)、急性呼吸功能衰竭(r=0.606,P=0.000)和糖尿病(r=0.372,P=0.012)与死亡有相关关系.结论 尽管急性心肌梗死合并心原性休克的治疗有了很大的发展,但病死率仍然较高,主要死因是急性心力衰竭、急性肾功能衰竭和急性呼吸功能衰竭.要进一步降低急性心肌梗死合并心原性休克患者住院病死率,可能需要更好的循环辅助装置及加强重要器官的保护.     

Early revascularization improves survival in cardiogenic shock complicating acute myocardial infarction.

The effects of coronary revascularization by percutaneous transluminal coronary angioplasty or coronary bypass grafting, or both, on survival were evaluated in 81 patients with cardiogenic shock complicating acute myocardial infarction. Thirty-two patients had successful revascularization and 49 patients had unsuccessful or no revascularization. Revascularization was achieved by coronary angioplasty in 22 patients, coronary bypass surgery in 2 and angioplasty followed by bypass surgery in 8. No significant differences were noted between the two groups with regard to baseline clinical or hemodynamic variables. Intraaortic balloon counterpulsation was employed in 27 (84%) of the 32 patients in the group with revascularization and in 19 (39%) of the 49 patients without revascularization (p = 0.0006). The in-hospital survival was significantly better in the patients with--18 (56%) of 32--than in the patients without revascularization--4 (8%) of 49 (p less than 0.0001). At a mean follow-up period of 21 +/- 15 months, this survival difference persisted--16 (50%) of 32 patients with revascularization survived versus 1 (2%) of 49 patients without revascularization (p less than 0.0001). The mean time from the onset of shock to revascularization differed significantly between survivors (12.4 +/- 15 h) and nonsurvivors (58.5 +/- 93 h) in the group with revascularization (p = 0.0004). In the revascularization group, the in-hospital survival rate was 77% (17 of 22) when revascularization was performed within 24 h but only 10% (1 of 10) when it was performed after 24 h (p = 0.0006).(ABSTRACT TRUNCATED AT 250 WORDS)     

Intra-aortic balloon counterpulsation improves survival in cardiogenic shock complicating acute myocardial infarction

The impact of intra-aortic balloon counterpulsation (IABC) onsurvival of patients with acute myocardial infarction (AMI)complicated by cardiogenic shock (CS) has been evaluated inthis study of 85 patients. IABC was available for the 24 groupA patients (and used in 20 patients). IABC was not availablefor the 21 group B patients who presented simultaneously withsimilar clinical characteristics and received identical pharmacologicaltreatment. In-hospital and one year survival was significantlyhigher in group A (46% and 38% vs 19% and 10%, P <0·001).Sixteen out of the 20 (group Al) IABC patients received earlycoronary revascularization. During 1980–1984, 35 patients with AMI and CS receivedIABC (group C) but none underwent early revascularization. Therewas no difference in in-hospital or one-year survival betweengroup AI (50% and 40%) and group C (45% and 40%). We concludethat early IABC improves survival of patients with AMI complicatedby CS.     

脉搏指数连续心输出量监测在急性心肌梗死合并心源性休克患者中的应用

目的探讨脉搏指数连续心输出量监测(PICCO)在急性心肌梗死(AMI)合并心源性休克(CS)患者中的应用价值。方法入选2012年1月至2013年1月因AMI合并心源性休克(CS)入住南京鼓楼医院集团宿迁市人民医院心血管内科重症监护病房(CCU)患者56例。其中男性35例,女性21例,年龄28~75岁,平均(56.5±2.3)岁。随机分成PICCO组(27例)及对照组(29例)。对照组入CCU后立即监测血压,心率,呼吸次数,血氧饱和度及心电图,记录体温变化,深静脉穿刺监测中心静脉压(CVP)。PICCO组在此基础上,进行深静脉置管+股动脉置管+PICCO模块连接。监测心脏指数(CI),血管外肺水指数(EVLWI)及血清N-末端脑钠肽前体(NT-pro BNP)变化情况。结果与PICCO治疗24 h比较,治疗48 h EVLWI[(8.85±0.73)ml/kg vs.(7.41±1.36)ml/kg]下降,CI[(2.21±0.45)L/min·m2 vs.(2.60±0.17)L/min·m2]增加,NT-pro BNP[(4069.48±65.32)pg/ml vs.(3721±20.32)pg/ml]下降,差异具有统计学意义(P0.05)。随着时间延长,EVLWI下降,CI增加,NT-pro BNP呈降低的趋势。同时,EVLWI与NT-pro BNP呈直线正相关(r=0.78,P0.05)。PICCO组患者血管活性药物使用时间,入住CCU时间,机械通气时间,病死率以及出院时血清NT-pro BNP水平明显低于对照组,差异有统计学意义(P均0.05)。结论 PICCO对于AMI合并CS患者的治疗具有重要价值。     

Mortality prognostic factors of cardiogenic shock complicating an acute myocardial infarction and treated by percutaneous coronary intervention

OBJECTIVE: To determine the in-hospital prognosis and late outcome of cardiogenic shock complicating acute myocardial infarction treated by early (< 24 hours) percutaneous coronary intervention (PCI). METHODS: Retrospective monocentric study of a consecutive cohort of patients undergoing early PCI (< 24 heures) for cardiogenic shock complicating acute myocardial infarction from 1994 to 2004. RESULTS: The cohort included 175 patients (mean age = 65 +/- 14 years, 68% male). A successful PCI was obtained in 69% of patients. The in-hospital mortality was 43%. Independent risk factors associated with an increased mortality were: absence of TIMI three flow (P < 0.0001), absence of smoking (P < 0.009) and the need for mechanical ventilation (P < 0.002). Nor stent use or anti GP IIb/IIa infusions were predictors of a better outcome. At hospital discharge, mean left ventricular ejection fraction (LVEF) was 38 +/- 12%. Kaplan-Meier estimate of survival was 63% for in-hospital survivors (maximum follow-up = 9 years). Independent predictors of an impaired long-term outcome were: a LVEF < 0.3 (P < 0.028) and 3-vessel disease on coronary angiography (P < 0.004). CONCLUSION: In-hospital mortality of patients suffering cardiogenic shock complicating acute myocardial infarction and treated by PCI remains high despite PCI improvement. The long-term survival appears, however, to be better than that of patients with coronary artery disease and low LVEF.     

Effect of vasopressin on hemodynamics in patients with refractory cardiogenic shock complicating acute myocardial infarction

In a retrospective study of 36 patients who developed cardiogenic shock after myocardial infarction, intravenous vasopressin therapy increased mean arterial pressure from 56 to 73 mm Hg at 1 hour (p < 0.001) and maintained it for 24 hours without changing pulmonary capillary wedge pressure, cardiac index, urine output, or other inotropic requirements. After norepinephrine administration, mean pulmonary capillary wedge pressure increased at 1 hour from 21 to 24 mm Hg (p = 0.04); however, this increase was not sustained at 12 and 24 hours. Norepinephrine was associated with a significant increase in cardiac power index at 24 hours, whereas there was only a trend for an increase in cardiac power with vasopressin therapy. In a cohort of patients who developed refractory cardiogenic shock after myocardial infarction, vasopressin was associated with increased mean arterial pressure and no adverse effect on other hemodynamic parameters.     

Challenges in the conduct of randomised controlled trials in cardiogenic shock complicating acute myocardial infarction

Cardiogenic shock (CS) following acute myocardial infarction (AMI) is a major challenge in cardiovascular care. Mortality remains high with 40%−50% after thirty days. Randomised controlled trials (RCTs) play a key role to generate evidence on optimal care in this field. However, the number of completed or ongoing RCTs is still relatively low compared to the gaps in evidence. Challenges in the conduct of these trials are in particular the selection of patients and ethical issues in the informed consent process. When determining eligibility criteria, special attention should be paid to the severity of CS, to the inclusion of patients with cardiac arrest and to potential age limits. Median age of AMI-CS patients is increasing. Age limits are therefore controversial as it is important to include elderly patients in RCTs in order to make the results generalisable and to address the special needs of this group. As patients with AMI-CS are in most cases unable to provide informed consent themselves, a step-wise approach with acute consent by a legal representative or independent physicians and later informed consent by the patient if possible might be established depending on regularities of the respective ethical review board and country legislation. Multicenter studies should be sought to generate adequate power.

Cardiogenic shock (CS) following acute myocardial infarction (AMI) remains a major challenge in cardiovascular care. Between 5% and 13% of patients with AMI develop CS, resulting in 60,000 to 70,000 patients being affected each year in Europe.^[1–4] Despite major advances in interventional and intensive care treatment, mortality of AMI-CS remains high, reaching 40%−50% at thirty days after hospital admission.^[5,6] Short-term mortality of elderly patients with AMI-CS is particularly high with up to 79% in patients aged ≥ 75 years.^[7] Clinical trials, especially in randomised designs, play a key role to a better understanding and treatment guidance in AMI-CS.     

Circulatory support for cardiogenic shock due to acute myocardial infarction: a Canadian experience.

BACKGROUND: Cardiogenic shock due to acute myocardial infarction (AMI) is associated with high mortality. Circulatory support devices may be used to assist these patients while they await cardiac transplantation. METHODS AND RESULTS: From 1986 to 1997, 25 patients in cardiogenic shock complicating AMI within 3.6+/-0.7 days of the event were supported with artificial hearts. Of the 25 patients, 21 were men with a mean age of 48.4 +/- 1.8 years. The age range was 26 to 62 years. Patients were considered for a device when the following criteria were met: cardiac index less than 1.8 L/min/m2, wedge pressure greater than 20 mmHg despite one or two inotropes and/or intra-aortic balloon support. They received either a CardioWest total artificial heart (n=13), a Thoratec biventricular assist device (n=6) or left ventricular assist device (LVAD) (n=6). Three patients were not considered transplant candidates and died while on the devices (two with multiorgan failure and one found to have a bronchogenic carcinoma after implant), with 22 undergoing cardiac transplantation within 8.6+/-2.2 days of device implant. Six patients died in hospital after the transplants (27.3% mortality). Complications included bleeding or tamponade in seven (28%), pneumonia in six (24%) and right ventricular failure in three LVAD patients (12%). Post-transplant actuarial one-, two- and five-year survival rates were 71.4%, 71.4% and 51%, respectively. CONCLUSIONS: Circulatory support devices offer a means to maintain organ perfusion in patients who develop cardiogenic shock due to AMI. Patients can then undergo transplantation with a reasonable expectation for survival when the alternative is death. Eventually the availability of permanent support devices may obviate the need for transplant in these patients.